- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02881970
Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells (NEOSTEM)
Neonatal hypoxic-ischaemic encephalopathy is a dramatic perinatal complication due to brain asphyxia. Neurological and neurosensory sequelae are frequent in survivors, due to neuronal damage and loss.
Currently, only total or partial body hypothermia can partially prevent cell loss. However, no treatment exists to restore neuronal functions.
Cord blood stem cells are a promising treatment for the near future.
The primary objective of this study is to test the safety and feasibility of a curative treatment with autologous cord blood stem cell in neonatal hypoxic-ischaemic encephalopathy.
The secondary objectives are to test the efficacy of this curative treatment with cell with neurogenic potential on the prevention of neurologic sequelae, as well as to test the optimum timing of cell preparation administration
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Farid BOUBRED
- Email: farid.boubrd@ap-hm.fr
Study Locations
-
-
-
Marseille, France
- Recruiting
- Assistance Publique Hopitaux de Marseille
-
Contact:
- FARID BOUBRED
- Email: farid.boubred@ap-hm.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Term ≥ 36 weeks of gestation
- and (2) :
- a blood pH < 7 with base deficit > 12 mmol/l (at birth or within 60 minutes of age)
- or a blood pH between 7,01 and 7,15, with additionnal criteria:
- a history of acute perinatal event (e.g : abnormal fetal cardiac rate, cord prolapse, uterine rupture, maternal hemorrhage)
- and a 5 minutes Apgar score ≤ 5, or a continued need for resuscitation, including endotracheal or mask ventilation at 5 min after birth.
- signs of encephalopathy within 12 hours of age (Sarnat and Sarnat classification, score ≥ 2)
- ± abnormal electroencephalogram or aEEG within 12 hours of age
- therapeutic hypothermia.
- no maternal infection with VIH, HTLV 1 or 2, Hepatitis B or C virus.
- maternal negative serology for syphilis
- written parental consent
Exclusion Criteria:
- presence of known chromosomal anomaly.
- presence of major congenital anomalies. severe intrauterine growth restriction (weight <1800g)
- infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Neonatal hypoxic-ischaemic encephalopathy
|
Injection of 5.107 / kg autologous mononuclear cells from umbilical cord blood
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse clinical or paraclinical event rates due to stem cell preparation
Time Frame: 2years
|
2years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
- Preliminary efficacy as measured by neurodevelopmental function
Time Frame: 2years
|
2years
|
Collaborators and Investigators
Investigators
- Study Director: CATHERINE GEINDRE, AP HM
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-A01018-37
- 2013-32 (AP HM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Hypoxic-ischaemic Encephalopathy
-
Turku University HospitalNot yet recruitingNeonatal Stroke | Neonatal Hypoxic Ischemic Encephalopathy | Neonatal Encephalopathy, UnspecifiedFinland
-
Neonatal Encephalopathy Consortium, JapanNational Cerebral and Cardiovascular Center; Nagoya University; Tokyo Women's... and other collaboratorsUnknownNeonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy)Japan
-
University of Wisconsin, MadisonMeriter FoundationRecruitingHypoxic-Ischemic Encephalopathy | Neonatal Encephalopathy | EncephalopathyUnited States
-
University Children's Hospital, ZurichCompletedHypoxic Ischaemic EncephalopathySwitzerland
-
University College CorkKarolinska InstitutetCompletedAsphyxia | Hypoxic Ischaemic Encephalopathy (HIE)Sweden, Ireland
-
University of California, San DiegoUniversity of Minnesota; Rady Children's Hospital, San Diego; Middlemore Hospital... and other collaboratorsRecruitingHypoxic-Ischemic Encephalopathy | Neonatal Encephalopathy | Neonatal Seizure | Seizure NewbornUnited States, New Zealand
-
Assiut UniversityUnknownNeonatal Hypoxic Ischemic Encephalopathy
-
Assiut UniversityUnknownNeonatal Hypoxic Ischemic Encephalopathy
-
Neonatal Encephalopathy Consortium, JapanNational Cerebral and Cardiovascular Center; Nagoya University; Tokyo Women's... and other collaboratorsCompletedNeonatal Encephalopathy | Hypoxic-ischemic EncephalopathyJapan
-
University Hospital, BordeauxCompletedNeonatal Hypoxic Ischemic EncephalopathyFrance
Clinical Trials on autologous cord blood stem cell
-
Aryn KnightThe University of Texas Health Science Center, Houston; Baylor College of Medicine and other collaboratorsWithdrawnArterial Ischemic Stroke (AIS) in ChildrenUnited States
-
Charles CoxNo longer available
-
Neonatal Encephalopathy Consortium, JapanNational Cerebral and Cardiovascular Center; Nagoya University; Tokyo Women's... and other collaboratorsUnknownNeonatal Encephalopathy (Neonatal Hypoxic-ischemic Encephalopathy)Japan
-
Children's Hospital of Fudan UniversityThe First Affiliated Hospital of Zhengzhou University; Shanghai Children's... and other collaboratorsActive, not recruitingInflammatory Bowel DiseasesChina
-
Children's Hospital of Fudan UniversityThe First Affiliated Hospital of Zhengzhou University; Shanghai Children's... and other collaboratorsActive, not recruitingSevere Combined Immunodeficiency DiseaseChina
-
Guangdong Women and Children HospitalCompletedSafety Issues | Neonatal Death | Effect of Drugs
-
Aryn KnightM.D. Anderson Cancer Center; The University of Texas Health Science Center,... and other collaboratorsWithdrawn
-
China Medical University HospitalUnknownIschemia | Ischemic Stroke | Brain Ischemia | Infarction, Middle Cerebral Artery | Ischaemic Cerebral InfarctionTaiwan
-
Guangdong Women and Children HospitalUnknownSafety Issues | Effect of Drugs